An Arkansas diagnostic testing company has received authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 antibody test.
NOWDiagnostics, a Springdale-based company, announced that it had been granted Emergency Use Authorization (EUA) for its ADEXUSDx antibody test. This EUA is for use in “moderate-complex settings” and at the point-of-care.
With this authorization, NOWDiagnostics plans to offer its test to Clinical Laboratory Improvement Amendment (CLIA)-waived facilities, such as pharmacies, clincis, emergency rooms and others. According to the company, the test can detect and measure the presence of COVID-19 antibodies in 15 minutes.
“The ADEXUSDx® COVID-19 Test is literally a lab at the tip of your finger, specifically designed to make diagnostic testing possible at home. This EUA approval is the first step in making that a reality. The ADEXUSDx® COVID-19 Test uses the same platform as our other FDA-cleared and/or CE marked, next-generation tests which are affordable, portable, and deliver laboratory-quality results in minutes without any additional supplies. We believe antibody testing is essential to America’s recovery from the COVID-19 pandemic, especially with the ongoing roll out of vaccines, and we’re proud to be responding to the urgent need for a reliable COVID-19 antibody test that targets the spike protein with our made-in-the-U.S.A. product,” NOWDiagnostic CEO Kevin Clark said in a statement.
The company originally applied for moderate complexity testing for the test in May 2020. The company then provided point-of-care data to the FDA in November 2020 to expand the application.
READ MORE: Ten Reappointed to State Board of Health With One New Appointment
